Panacea Life Sciences Holdings Shareholders’ Equity Growth & History (PLSH)
Panacea Life Sciences Holdings's shareholders’ equity was −$8.3M for fiscal 2023.
View full Panacea Life Sciences Holdings company overviewPanacea Life Sciences Holdings annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | −$8.3M | −$6.1M | — |
| 2022 | 2022-12-31 | −$2.1M | −$9.2M | — |
| 2021 | 2021-12-31 | $7.1M | $394,103 | +5.87% |
| 2020 | 2020-12-31 | $6.7M | −$5.2M | −43.82% |
| 2019 | 2019-12-31 | $11.9M | $15.4M | — |
| 2018 | 2018-12-31 | −$3.4M | −$1.2M | — |
| 2017 | 2017-12-31 | −$2.2M | −$3.7M | — |
| 2016 | 2016-12-31 | $1.5M | $1.6M | — |
| 2015 | 2015-12-31 | −$93,320 | −$139,084 | — |
| 2014 | 2014-12-31 | $45,764 | — | — |
Panacea Life Sciences Holdings quarterly shareholders’ equity
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | $3.8M | — | — |
| Q2 2025 | 2025-06-30 | −$9.9M | — | — |
| Q1 2025 | 2025-03-31 | −$10.5M | −$888,251 | — |
| Q1 2024 | 2024-03-31 | −$9.6M | −$5.8M | — |
| Q4 2023 | 2023-12-31 | −$8.3M | −$6.1M | — |
| Q3 2023 | 2023-09-30 | −$6.1M | −$5.6M | — |
| Q2 2023 | 2023-06-30 | −$5.6M | −$7.8M | — |
| Q1 2023 | 2023-03-31 | −$3.8M | −$8.0M | — |
| Q4 2022 | 2022-12-31 | −$2.1M | −$9.2M | — |
| Q3 2022 | 2022-09-30 | −$439,907 | −$8.8M | — |
| Q2 2022 | 2022-06-30 | $2.3M | −$9.2M | −80.37% |
| Q1 2022 | 2022-03-31 | $4.2M | −$2.9M | −40.94% |
| Q4 2021 | 2021-12-31 | $7.1M | $394,103 | +5.87% |
| Q3 2021 | 2021-09-30 | $8.4M | $1.6M | +23.54% |
| Q2 2021 | 2021-06-30 | $11.5M | $909,643 | +8.60% |
| Q1 2021 | 2021-03-31 | $7.1M | −$3.2M | −31.04% |
| Q4 2020 | 2020-12-31 | $6.7M | −$5.2M | −43.82% |
| Q3 2020 | 2020-09-30 | $6.8M | −$960,507 | −12.38% |
| Q2 2020 | 2020-06-30 | $10.6M | $6.2M | +140.92% |
| Q1 2020 | 2020-03-31 | $10.3M | $7.6M | +287.67% |
| Q4 2019 | 2019-12-31 | $11.9M | $15.4M | — |
| Q3 2019 | 2019-09-30 | $7.8M | $11.9M | — |
| Q2 2019 | 2019-06-30 | $4.4M | $7.3M | — |
| Q1 2019 | 2019-03-31 | $2.6M | $5.0M | — |
| Q4 2018 | 2018-12-31 | −$3.4M | −$1.2M | — |
| Q3 2018 | 2018-09-30 | −$4.1M | −$3.8M | — |
| Q2 2018 | 2018-06-30 | −$2.9M | −$3.4M | — |
| Q1 2018 | 2018-03-31 | −$2.4M | −$3.3M | — |
| Q4 2017 | 2017-12-31 | −$2.2M | −$3.7M | — |
| Q3 2017 | 2017-09-30 | −$300,095 | −$947,560 | — |
| Q2 2017 | 2017-06-30 | $417,724 | −$464,554 | −52.65% |
| Q1 2017 | 2017-03-31 | $924,021 | $780,869 | +545.48% |
| Q4 2016 | 2016-12-31 | $1.5M | $1.6M | — |
| Q3 2016 | 2016-09-30 | $647,465 | $713,428 | — |
| Q2 2016 | 2016-06-30 | $882,278 | $884,231 | — |
| Q1 2016 | 2016-03-31 | $143,152 | — | — |
| Q4 2015 | 2015-12-31 | −$93,320 | −$139,084 | — |
| Q3 2015 | 2015-09-30 | −$65,963 | — | — |
| Q2 2015 | 2015-06-30 | −$1,953 | — | — |
| Q4 2014 | 2014-12-31 | $45,764 | — | — |
Panacea Life Sciences Holdings shareholders’ equity trends
Over the last five fiscal years, Panacea Life Sciences Holdings's shareholders’ equity decreased from −$3.4M to −$8.3M, a change of −$4.9M. The latest reported quarter, Q3 2025, shows $3.8M.
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Panacea Life Sciences Holdings source filings ↗